Jinan University, Guangzhou, China.
Pathobiology. 2012;79(6):285-9. doi: 10.1159/000331229. Epub 2012 Jun 9.
Coxsackievirus B3 (CVB3) is a dominant causative agent for viral myocarditis. So far, effective therapies for the treatment of the disease are not available. 20(S)-Protopanaxtriol is a major component of Panax pseudoginseng and has been clinically used for the treatment of heart diseases. However, it is not known whether 20(S)-protopanaxtriol exerts any anti-viral effects. Thus, the aim of this study was to investigate the therapeutic effects of 20(S)-protopanaxtriol against CVB3 in vivo and in vitro.
The antiviral effects of 20(S)-protopanaxtriol in vitro were evaluated in HeLa cells infected by CVB3. Then, we examined the protective effects of 20(S)-protopanaxtriol on CVB3-induced myocarditis in BALB/c mice. These mice were treated with 20(S)-protopanaxtriol at doses of 100-400 mg·kg(-1)·day(-1) for 7 days and compared with the controls.
We found that 20(S)-protopanaxtriol possessed potent antiviral effects on CVB3 in vitro. Compared with control mice, virus titers and pathological changes in the hearts were significantly decreased in the 20(S)-protopanaxtriol-treated group. Furthermore, biochemical markers of myocardial injury such as plasma lactate dehydrogenase and creatine kinase were decreased to normal levels.
These data provide the possibility that 20(S)-protopanaxtriol can be used as a potential therapeutic means for treatment of viral myocarditis.
柯萨奇病毒 B3（CVB3）是病毒性心肌炎的主要致病因子。目前，针对该疾病还没有有效的治疗方法。20(S)-原人参三醇是人参的主要成分之一，已在临床上用于治疗心脏病。然而，目前尚不清楚 20(S)-原人参三醇是否具有抗病毒作用。因此，本研究旨在探讨 20(S)-原人参三醇在体内和体外抗 CVB3 的治疗效果。
在 HeLa 细胞中用 CVB3 感染，评估 20(S)-原人参三醇的体外抗病毒作用。然后，我们检测了 20(S)-原人参三醇对 BALB/c 小鼠 CVB3 诱导心肌炎的保护作用。这些小鼠用 20(S)-原人参三醇以 100-400mg·kg(-1)·d(-1)的剂量治疗 7 天，并与对照组进行比较。
我们发现 20(S)-原人参三醇在体外对 CVB3 具有很强的抗病毒作用。与对照组小鼠相比，20(S)-原人参三醇治疗组的病毒滴度和心脏病理变化明显降低。此外，心肌损伤的生化标志物如血浆乳酸脱氢酶和肌酸激酶也恢复至正常水平。
这些数据为 20(S)-原人参三醇可作为治疗病毒性心肌炎的潜在治疗手段提供了可能性。
